Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma

Despite recent therapeutic advances that have doubled the median survival time of patients with multiple myeloma (MM), intratumor genetic heterogeneity contributes to disease progression and emergence of drug resistance. MicroRNAs (miRs), are noncoding small RNAs that play important roles in the reg...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Res
Auteurs principaux: Zhao, Jian-Jun, Chu, Zhang-Bo, Hu, Yu, Lin, Jianhong, Wang, Zhongqiu, Jiang, Meng, Chen, Ming, Wang, Xujun, Kang, Yue, Zhou, Yangsheng, Ni Chonghaile, Triona, Johncilla, Melanie E., Tai, Yu-Tzu, Cheng, Jin Q., Letai, Antony, Munshi, Nikhil C., Anderson, Kenneth C., Carrasco, Ruben D.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4609291/
https://ncbi.nlm.nih.gov/pubmed/26249174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0457
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires